Search





Search





Markets
/
Stocks
/
nasdaq-armp
/

Armata Pharmaceuticals Inc

ARMP

Add to Watchlist

8.050USD

-0.160-1.95%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

295.52MMarket Cap

LossP/E TTM



Armata Pharmaceuticals Inc

8.050

-0.160-1.95%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Armata Pharmaceuticals Inc

Currency: USD Updated: 2026-05-15

Key Insights

Armata Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 140 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Armata Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

140 / 382

Overall Ranking

269 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Armata Pharmaceuticals Inc Highlights

StrengthsRisks

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.90M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.90M.

Overvalued

The company’s latest PE is -1.04, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.35M shares, increasing 43.39% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 68.50K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.500

Target Price

+113.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Armata Pharmaceuticals Inc is 6.68, ranking 213 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.68

Change



Financials

4.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.97

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.71

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.43

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Armata Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Armata Pharmaceuticals Inc is 6.45, ranking 266 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.04, which is -100.00% below the recent high of 0.00 and -20748.74% above the recent low of -215.85.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 140/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Armata Pharmaceuticals Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 9.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.500

Target Price

+113.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Armata Pharmaceuticals Inc

ARMP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Armata Pharmaceuticals Inc is 6.81, ranking 148 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 12.85 and the support level at 5.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.483

Sell

RSI(14)

38.351

Neutral

STOCH(KDJ)(9,3,3)

15.044

Oversold

ATR(14)

1.332

Low Volatility

CCI(14)

-134.733

Sell

Williams %R

88.248

Oversold

TRIX(12,20)

-1.099

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

8.578

Sell

MA10

8.861

Sell

MA20

10.273

Sell

MA50

10.316

Sell

MA100

9.008

Sell

MA200

6.623

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Armata Pharmaceuticals Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.14%, representing a quarter-over-quarter increase of 320.60%. The largest institutional shareholder is James Simons, holding a total of 68.50K shares, representing 0.19% of shares outstanding, with 75.14% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Innoviva Inc

25.08M

683 Capital Management LLC

139.86K

Geode Capital Management, L.L.C.

109.89K

+5.11%

Edgewood Management LLC

100.00K

Renaissance Technologies LLC

Star Investors

68.50K

+65.87%

BlackRock Institutional Trust Company, N.A.

61.79K

+150.28%

Pastagia (Mina M.D.)

61.08K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Armata Pharmaceuticals Inc is 1.24, ranking 323 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.